Core Viewpoint - The document outlines the information disclosure management system for Chongqing Zhifei Biological Products Co., Ltd., emphasizing the importance of timely, accurate, and comprehensive disclosure of bond-related information to protect investors' rights and comply with regulatory requirements [1][2][3]. Group 1: General Provisions - The system is established to regulate the disclosure of bond information, ensuring compliance with relevant laws and regulations [1]. - The company must disclose information that may significantly impact its debt repayment ability or investors' rights [1][2]. - Information must be based on objective facts and should not contain false statements or misleading content [2][3]. Group 2: Disclosure Content and Standards - Required disclosures include issuance and fundraising information, periodic reports, and temporary reports [7]. - Negative events must be disclosed with a comprehensive analysis of their impact on debt repayment ability and the measures taken in response [3][4]. - The company can voluntarily disclose additional relevant information, ensuring it does not conflict with legally required disclosures [3][4]. Group 3: Disclosure Procedures - The company must follow specific procedures for disclosing periodic and temporary reports, involving various management levels for review and approval [17][18]. - Timely disclosure of significant events is required within two trading days of becoming aware of such events [5][6]. Group 4: Responsibilities and Management - The board of directors is responsible for overseeing information disclosure, with the chairman as the primary responsible person [21][22]. - The board secretary coordinates disclosure activities and ensures compliance with legal and regulatory requirements [22][23]. - The audit committee monitors the information disclosure practices of the company's directors and senior management [13]. Group 5: Subsidiary Disclosure Management - Subsidiaries must appoint personnel responsible for information disclosure and report relevant information to the parent company [29][30]. - Significant events at subsidiaries that may affect the company's financial status must be reported in accordance with the established system [30][31]. Group 6: Implementation and Amendments - The system becomes effective upon approval by the board of directors and is subject to amendments as necessary [32][33]. - Any matters not covered by the system will follow applicable laws, regulations, and the company's internal management rules [32][33].

Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd. plans to issue corporate bonds to raise funds for technological innovation, debt restructuring, and working capital needs, with a total issuance scale not exceeding RMB 6 billion [1][2]. Group 1: Issuance Overview - The proposed bond issuance scale is up to RMB 60 billion, with the specific amount to be determined based on the company's funding needs and market conditions [2]. - The bonds will be issued through a book-building method, which may involve either a single issuance or multiple issuances [2]. - The face value of the bonds will be RMB 100, issued at par [2]. - The bonds will be offered to qualified professional investors, without preferential allocation to existing shareholders [2]. - The issuance will occur at an opportune time based on actual funding needs, on the Shenzhen Stock Exchange [2]. - The bond term will not exceed 10 years, including both public and private placements [2]. Group 2: Fund Utilization and Terms - The funds raised will be used for investments in technological innovation, debt replacement, and working capital, with specific allocations to be determined by the board [2][3]. - The bonds will have a fixed interest rate, determined through a pricing inquiry process, with interest paid annually and principal repaid at maturity [3]. - The bonds will be issued without collateral [4]. - The underwriting will be conducted through a firm commitment basis, with plans for listing on the Shenzhen Stock Exchange post-issuance [4]. Group 3: Authorization and Approval Process - The board seeks authorization from the shareholders' meeting to manage all aspects of the bond issuance, including terms and conditions [5][6]. - The issuance has been approved by the board and supervisory committee but requires shareholder approval and regulatory clearance before proceeding [6].

证券代码：300122 证券简称：智飞生物 公告编号：2025-36 重庆智飞生物制品股份有限公司 关于发行公司债券预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日 召开了第六届董事会第六次会议、第六届监事会第五次会议，审议通过了《关于 发行公司债券的议案》《关于提请股东大会授权董事会并由董事会授权董事长全 权办理本次发行公司债券相关事项的议案》等相关议案，本次发行公司债券事项 尚需提交公司股东大会审议。现将相关事项公告如下： 一、关于符合发行公司债券条件的说明 为促进公司稳健发展，加速推动科技创新，拓宽融资渠道，满足生产经营与 投资的资金需求，优化债务结构，经慎重考虑，公司拟通过在境内申请发行公司 债券的方式筹集资金。经逐项对照《中华人民共和国公司法》《中华人民共和国 证券法》《公司债券发行与交易管理办法》和《深圳证券交易所公司债券上市规 则》等法律、法规、部门规章、规范性文件和深圳证券交易所业务规则中关于公 开发行及非公开发行公司债券条件的规定，董事会、监事会认为 ...

第一条 为规范重庆智飞生物制品股份有限公司（以下简称"公司"）债券 （含企业债券）募集资金的管理与使用，保护投资者的合法权益，提高募集资金 使用效益，根据《中华人民共和国公司法》《中华人民共和国证券法》《公司债券 发行与交易管理办法》《深圳证券交易所公司债券上市规则》等法律、行政法规、 规范性文件、深圳证券交易所的相关规定以及《重庆智飞生物制品股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，结合本公司实际情况，制定本 制度。 第二条 本制度所称募集资金是指公司通过公开或非公开发行公司债券向投 资者募集的资金。 第三条 募集资金的使用和管理要履行公司决策和审批程序。公司应按约定 的用途使用募集资金，并根据相关法律法规、发行文件的规定和约定，及时披露 募集资金使用情况。 重庆智飞生物制品股份有限公司 债券募集资金管理与使用制度 重庆智飞生物制品股份有限公司 债券募集资金管理与使用制度 第一章 总则 重庆智飞生物制品股份有限公司 债券募集资金管理与使用制度 第六条 公司应当审慎选择商业银行并开设募集资金专项账户(以下简称"专 户") 用于公司债券募集资金的接收、存储、划转，募集资金应存放于专户集中 管理 ...

重庆智飞生物制品股份有限公司 债券信息披露管理制度 重庆智飞生物制品股份有限公司 债券信息披露管理制度 第一章 总则 第一条 为规范重庆智飞生物制品股份有限公司（以下简称"公司"）的债券 （含企业债券）信息披露工作，保护投资者合法权益，根据《中华人民共和国公司 法》《中华人民共和国证券法》（以下简称"《证券法》"）《公司债券发行与交 易管理办法》《深圳证券交易所公司债券上市规则》等法律、行政法规、规范性文 件、深圳证券交易所的相关规定以及《重庆智飞生物制品股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，结合本公司实际情况，制定本制度。 第二条 公司债券的发行及存续期信息披露适用本制度。 第三条 本制度所称公司债券，是指公司在证券交易所发行的，约定在一定 期限内还本付息的有价证券，包括但不限于公开发行公司债券、非公开发行公司债 券等。 本制度所称信息，是指公司作为证券交易所债券发行主体，在公司债券申报、 发行及存续期内，对公司偿债能力或投资者权益可能有重大影响的信息，以及中国 证券监督管理委员会（以下简称"中国证监会"）和证券交易所要求披露的其他信 息。 第四条 公司披露信息时，应当以客观事实或者具 ...

1、股东大会届次：本次股东大会为重庆智飞生物制品股份有限公司（以下 简称"公司"）2025 年第一次临时股东大会。 2、股东大会的召集人：公司董事会 证券代码：300122 证券简称：智飞生物 公告编号：2025-37 重庆智飞生物制品股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 3、会议召开的合法、合规性：经公司第六届董事会第六次会议审议通过， 公司召开 2025 年第一次临时股东大会，会议的召集符合有关法律、行政法规、 部门规章、规范性文件、深圳证券交易所业务规则和公司章程等的规定。 4、会议召开的日期、时间： （1）现场会议召开日期和时间：2025 年 7 月 14 日（星期一）10:00； （2）网络投票日期和时间：2025 年 7 月 14 日。其中，通过深圳证券交易 所交易系统进行网络投票的时间为 2025 年 7 月 14 日 9:15-9:25、9:30-11:30， 13:00-15:00；通过深圳证券交易所互联网系统投票的具体时间为 2025 年 7 月 ...

第六届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300122 证券简称：智飞生物 公告编号：2025-35 重庆智飞生物制品股份有限公司 1、审议通过了《关于发行公司债券预案的议案》 一、监事会会议召开情况 1、本次监事会于 2025 年 6 月 25 日以电子邮件的方式向监事发出通知。 2、本次会议于 2025 年 6 月 26 日 11:00 在公司会议室以现场结合通讯方式 召开。 3、本次会议应出席并参加表决的监事 3 人，实际出席并参加表决的监事 3 人。 4、本次会议由公司监事会主席荀婕女士主持。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和公司章程的规定。 二、监事会会议审议情况 经过认真审议，本次会议形成了如下决议： 为促进公司稳健发展，加速推动科技创新，拓宽融资渠道，满足生产经营与 投资的资金需求，优化债务结构，经慎重考虑，公司拟通过在境内申请发行公司 债券的方式筹集资金。监事会同意发行公司债券规模合计不超过人民币 60 亿元 （含人民币 60 亿元）。具体发行规模 ...

第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会于 2025 年 6 月 25 日以电子邮件的方式向董事发出通知。 证券代码：300122 证券简称：智飞生物 公告编号：2025-34 重庆智飞生物制品股份有限公司 2、本次会议于 2025 年 6 月 26 日 10:00 在公司会议室以现场结合通讯方式 召开。 3、本次会议应出席并参加表决的董事 9 人，实际出席并参加表决的董事 9 人。 4、本次会议由公司董事长蒋仁生先生主持，公司监事、高级管理人员列席 了本次会议。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件及公司章程的规定。 二、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： 1、审议通过了《关于发行公司债券预案的议案》 为促进公司稳健发展，加速推动科技创新，拓宽融资渠道，满足生产经营与 投资的资金需求，优化债务结构，经慎重考虑，公司拟通过在境内申请发行公司 债券的方式筹集资金。董事会同意发行公司债券规模合计不超过人民币 60 ...

Core Viewpoint - The 2025 New Fortune 500 Rich List reveals a significant increase in the total market value of listed entrepreneurs, reaching 13.7 trillion yuan, an 11% year-on-year growth, indicating a new wave of wealth creation driven by innovation and overseas expansion [3][14]. Group 1: Wealth Distribution and Rankings - The top ten wealthiest individuals are heavily influenced by AI, with Zhang Yiming of ByteDance topping the list with a holding value of 481.57 billion yuan, marking a 42% increase from the previous year [4][18]. - The list features a notable shift, with four individuals from Hangzhou, Zhejiang, highlighting the region's growing economic prominence [43]. - The average holding value of the 500 entrepreneurs is 273.8 million yuan, with a threshold of 66.2 million yuan to make the list [8]. Group 2: Industry Insights - The TMT (Technology, Media, and Telecommunications), pharmaceutical, and daily consumer goods sectors are the top three wealth-generating industries, contributing 110, 54, and 52 individuals respectively [51]. - The TMT sector saw a significant increase in wealth, with a total of 334.08 billion yuan, a 46% increase from the previous year [51]. - The pharmaceutical sector experienced a decline, with 54 individuals listed, down from 64, indicating ongoing valuation adjustments [51]. Group 3: AI and Technological Advancements - AI has emerged as a key driver of wealth creation, with companies like DeepSeek and ByteDance leading the charge in user engagement and valuation [4][21]. - The rise of AI has also led to a resurgence in the semiconductor industry, with China exporting 2.981 billion chips worth approximately 159.5 billion USD, marking a significant shift in the global market [56]. - The AI sector is still in its nascent stage, with notable entries like Liang Wenfeng of DeepSeek entering the top ten, reflecting the rapid growth and potential of AI applications [60]. Group 4: Regional Wealth Creation - Wealth creation is becoming more balanced across regions, with western provinces like Sichuan, Tibet, and Xinjiang seeing an increase in listed individuals, while traditional economic hubs like Zhejiang and Shanghai continue to grow [5][6]. - The shift from real estate to technology and AI reflects a broader transformation in China's economic landscape, with younger entrepreneurs increasingly dominating the wealth rankings [46][45]. Group 5: Future Outlook - The ongoing evolution of industries, particularly in AI and technology, suggests a promising future for innovation-driven wealth creation in China [60][62]. - The integration of AI into various sectors, including automotive and consumer electronics, is expected to further enhance China's competitive edge in the global market [62][63].

Financial Performance - As of June 20, 2025, Zhifei Biological reported a closing price of 19.02 yuan, with a slight increase of 0.42% [1] - The total operating revenue for the first quarter of 2025 was 2.374 billion yuan, representing a year-on-year decrease of 79.16% [1] - The net profit attributable to shareholders was approximately 305.14 million yuan, down 120.93% year-on-year [1] - The company's current ratio is 2.298, quick ratio is 1.029, and debt-to-asset ratio stands at 36.85% [1] Market Activity - The trading volume was 222,300 hands, with a total transaction amount of 425 million yuan [1] - The net inflow of main funds was 38.55 million yuan, accounting for 9.06% of the transaction amount [1] - Large orders saw a net inflow of 44.10 million yuan, while small orders experienced a net outflow of 42.67 million yuan [1] Company Overview - Zhifei Biological, established in 1995, is located in Chongqing and primarily engages in the pharmaceutical manufacturing industry [2] - The company has a registered capital of approximately 2.39 billion yuan and a paid-in capital of 400 million yuan [1] - Zhifei Biological has made investments in 9 companies and participated in 1,149 bidding projects [2]